All In MedTech

Device Trial Radar · NCT04583215

Enhancing Frontal Lobes Plasticity in Mild Cognitive Impairment

Enhancing Frontal Lobes Plasticity and Function in Patients With Mild Cognitive Impairment

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 12, 2020

Primary completion

Aug 14, 2026

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Centre for Addiction and Mental HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 12, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

More than 5 million people live with Alzheimer's dementia (AD) in North America. No effective treatment exists yet probably because by the time AD has developed it is too late to intervene. Mild Cognitive Impairment (MCI) is a clinical state that typically precedes AD. In MCI, the prefrontal cortex supports compensatory mechanisms that depend on robust synaptic plasticity and that delay progression to AD. Using a neurostimulation approach that enhances prefrontal cortical plasticity in vivo, this project aims to enhance prefrontal cortical plasticity and function in patients with MCI. If successful, this project would discover a treatment modality that enhances compensation in MCI and ultimately, prevents progression to AD.

Conditions

  • Mild Cognitive Impairment
  • Memory Impairment

Interventions

  • Paired Associative Stimulation (PAS)Device

    On each of the 10 days of the intervention, participants will receive PAS (or PAS-C) to the left DLPFC by delivering peripheral nerve stimulation (PNS) to the right median nerve and TMS to the left DLPFC, followed immediately by PAS (or PAS-C) to the right DLPFC by delivering PNS to the left median nerve and TMS to the right DLPFC. PAS-C differs from PAS only by including an interstimulus interval of 100 ms between PNS and TMS to the DLPFC, compared to 25 ms in the active PAS condition. Using 100 ms interval, we have previously demonstrated that PAS-C does not induce PAS-LTP in the DLPFC. If a participant cannot attend one or more of the 10 consecutive PAS or PAS-C treatment sessions, we will allow up to four extra treatment days to make up for missed sessions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PAS-Long-term-potentiation (PAS-LTP)Time frame: Baseline
  2. Change in PAS-Long-term-potentiation (PAS-LTP)Time frame: Baseline, immediately and 1 and 4 weeks following the 10-session course
  3. N-Back PerformanceTime frame: Baseline

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Addiction and Mental Health

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.